Harpoon Therapeutics

Biotech & Life Sciences · South San Francisco, United States · Founded 2015 · IPO 2019

Harpoon Therapeutics is a biotechnology company specializing in the development of novel immuno-oncology treatments. The company operates in the biopharmaceutical market, focusing on creating innovative therapies that engage T cells to target and destroy cancer cells. Harpoon's proprietary technology platform, known as TriTAC (Tri-specific T cell Activating Construct), is designed to harness the body's immune system to fight cancer and other serious diseases. The company primarily serves patients with cancer, aiming to provide new treatment options through its cutting-edge biologics. Harpoon Therapeutics generates revenue through partnerships, licensing agreements, and the development and commercialization of its proprietary therapies. Notably, Harpoon has an exclusive worldwide option and license agreement with AbbVie for HPN217, a BCMA-targeting TriTAC, and is expanding its discovery collaboration to include up to six additional targets. Keywords: immuno-oncology, T cell engagement, cancer therapy, TriTAC platform, antibody-based treatments, biotechnology, biopharmaceutical, immune system, biologics, AbbVie partnership.

Valuation $100–500M

Revenue $10–50M

Headcount <100

Total funding $100–500M

Power Law Colt$25–100M revenue

Investors

6 investors on Harpoon Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage

MPM BioImpact

Arix Bioscience

New Leaf Venture Partners

Taiho Pharma

Series B+ 2 investors entered at this stage

OrbiMed

Ridgeback Capital

Global footprint

Where Harpoon Therapeutics has talent and traffic

Workforce by country

🇺🇸 United States · South San Francisco HQ

Book a demo for the full country breakdown

Web traffic by country

350 monthly visits
across markets

🇺🇸 United States85.7%

🇿🇦 South Africa0%

🇹🇼 Taiwan0%

Top 3 markets shown

Talent graph

The shape of Harpoon Therapeutics's talent

Dealroom maps Harpoon Therapeutics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

15 team members profilednamed & role-tagged by Dealroom

22 employeestotal headcount

4 executives & foundersidentified by name

DimensionScore

AI Talent

Engineering

Product

Go-to-market

Leadership

Research

Book a demo to unlock Harpoon Therapeutics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Harpoon Therapeutics

An AI-synthesized read of the highest-engagement posts about Harpoon Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Harpoon Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles